Monitor Denali's upcoming Phase 1/2 data readout for DNL593 by end of 2026, which will be critical for validating the program's potential without Takeda's backing and determining future partnership or funding needs.
DNLI drugs
DNLI drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $19.38entry
- T+1 · 7mo ago +0.15%α +0.09% · $19.41
- T+5 · 7mo ago +0.21%α −3.93% · $19.42
- T+20 · 7mo ago −3.66%α −12.65% · $18.67
- T+60 · 5mo ago +34.06%α +20.59% · $25.98
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Denali Therapeutics announced that Takeda has terminated their 2018 collaboration agreement to co-develop and co-commercialize DNL593 for frontotemporal dementia, citing strategic reasons unrelated to efficacy or safety. Denali will regain full rights to the program and continue its clinical development independently, with Phase 1/2 data expected by end of 2026.
Key Facts
- Takeda terminated the 2018 collaboration agreement for DNL593 (PTV:PGRN) for FTD-GRN due to strategic considerations, not efficacy or safety issues
- All rights to DNL593 will revert to Denali 60 days after the April 3, 2026 notice
- Denali will have no further financial obligations to Takeda post-termination
- Denali plans to continue clinical development of DNL593 independently
- Data from the ongoing Phase 1/2 study in FTD-GRN patients is expected by end of 2026
Financial Impact
Loss of Takeda's financial support for DNL593 development; Denali assumes full funding responsibility
Risk Factors
- Increased financial burden on Denali to fund DNL593 development independently
- Loss of Takeda's commercialization expertise and resources for a potential future launch
- Clinical data expected in late 2026 may face delays or fail to meet efficacy endpoints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001714899-26-000042 |
| Exhibit: ex9912026pressrelease4326.htm | 0001714899-26-000042 |
| Document: 0001714899-26-000042-index-headers.html | 0001714899-26-000042 |
| Document: 0001714899-26-000042-index.html | 0001714899-26-000042 |
| Document: 0001714899-26-000042.txt | 0001714899-26-000042 |
Track record
17 reports on DNLI
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
- Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
- Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
- Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
- Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers